These preliminary findings on tirzepatide join a 2024 study, authored by some of the same Mayo Clinic researchers, which found that after 12 months, a greater proportion of postmenopausal women using semaglutide and hormone therapy achieved 10 percent or more total body weight loss than those taking just the GLP-1 drug
Kaplan W, Husler P, Klump H, Erhardt J, Sluis-Cremer N, Dirr H
Celebrate the Season with GLP-1 Friendly Holiday Mocktails As the holiday season rolls in, many of us look forward to celebrating with loved ones, cozy gatherings, and festive feasts
Injectable peptides, including TB-500 and BPC-157, are on the World Anti-Doping Agencys list of banned substances, and theyre also banned by the U.S